Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion’s Cash Dwindles to $179K

Premium

This story originally ran on July 27.

Vermillion's cash reserves continued depleting as its Chapter 11 bankruptcy case remained on hold and revenue streams were non-existent.

In a report filed with the US Bankruptcy Court in Delaware last week, the company said it had $179,242 in cash at the end of June, down from $371,382 at the start of the month.

As part of its bankruptcy filing, Vermillion has agreed to file monthly reports in lieu of quarterly reports. For June, the company said it received a total of $424 in revenues and spent $192,564, including $134,977 in administrative costs.

As of June 30 Vermillion said it had $190,831 in cash and cash equivalents. It reported total assets of $9.7 million and total liabilities of $33 million.

The firm filed for bankruptcy in late March [see PM 04/01/09]. Meanwhile, it is awaiting word from the US Food and Drug Administration on its 510(k) pre-market notification for its ovarian cancer test, OVA1.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.